Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages E646-E653

  Walker, Evan J ^a   Ko, Andrew H ^a   Holly, Elizabeth A ^a   Bracci, Paige M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer risk; Metformin; Pancreatic adenocarcinoma; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; INSULIN SECRETAGOGUE; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG USE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; QUESTIONNAIRE; RISK ASSESSMENT; SCORING SYSTEM; UNITED STATES; UNIVERSITY; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; PANCREATIC NEOPLASMS; RISK; STATISTICAL MODEL;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK;

EID: 84922242751     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29120     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. American Cancer Society. Cancer facts & figures 2013. Atlanta: American Cancer Society, 2013.
3. Gong Z, Holly EA, Bracci PM. Obesity and survival in population-based patients with pancreatic cancer in the San Francisco Bay Area. Cancer Causes Control 2012;23:1929-37.
4. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17.
5. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
6. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol 2013;107:1-7.
7. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996;156:2255-60.
8. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997;89:442-6.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
10. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921-9.
11. Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:843-52.
12. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011;47:1928-37.
13. Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83.
14. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012;29:1314-27.
15. Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 2012;18:2723-5.
16. Ooi GT, Tseng LY, Tran MQ, et al. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992;6:2219-28.
17. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
18. Bergmann U, Funatomi H, Yokoyama M, et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-11.
19. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010;11:390-401.
20. Wang LW, Li ZS, Zou DW, et al. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008;14:7192-8.
21. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.
22. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411.
23. Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013;37:207-18.
24. Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
26. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
27. Oliveria SA, Koro CE, Ulcickas Yood M, et al. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev 2008;2:47-57.
28. Ferrara A, Lewis JD, Quesenberry CP, Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923-9.
29. Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620-6.
30. Morden NE, Liu SK, Smith J, et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-71.
31. Van Staa TP, Patel D, Gallagher AM, et al. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-65.
32. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.
33. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-82.
34. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1996;17:2265-81.
35. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-60.
36. Leslie S, Thiebaud P. Using propensity score to adjust for treatment selection bias. SAS Glob Forum 2007; Paper 184.
37. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
38. Wolpin BM, Bao Y, Qian ZR, et al. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013;105:1027-35.
39. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331:81-4.
40. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134:95-101.
41. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-7.
42. Li D, Tang H, Hassan MM, et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011;22:189-97.
43. Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev 2005;14:2093-7.
44. Chan JM, Gong Z, Holly EA, et al. Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 2013;65:157-64.
45. Tranah GJ, Holly EA, Wang F, et al. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area. BMC Cancer 2011;11:138.